(MedPage Today) — The FDA authorized use of baricitinib (Olumiant), an oral Janus kinase (JAK) inhibitor, in combination with intravenous remdesivir (Veklury) to treat hospitalized patients with severe COVID-19, the agency said on Thursday.
The…
Read More